blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2451459

EP2451459 - METHOD OF REDUCING MULTI-DRUG RESISTANCE USING INOSITOL TRIPYROPHOSPHATE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  28.09.2018
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  20.10.2017
FormerGrant of patent is intended
Status updated on  02.05.2017
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): AL, IS
published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Normoxys, Inc.
16 Laurel Avenue Suite 150
Wellesley, MA 02481 / US
For all designated states
Université de Strasbourg
4, rue Blaise Pascal
67000 Strasbourg / FR
[2017/47]
Former [2012/20]For all designated states
Normoxys, Inc.
16 Laurel Avenue Suite 150
Wellesley, MA 02481 / US
For all designated states
Université de Strasbourg
4, rue Blaise Pascal
67000 Strasbourg / FR
Inventor(s)01 / NICOLAU, Yves, Claude
166 Greenwood Street
Newton MA 02459 / US
02 / LEHN, Jean-marie
6 Rue Des Pontoniers
F-67000 Strasbourg / FR
03 / KIEDA, Claudine
2 Rue De La Tour
F-45000 Orleans / FR
 [2012/20]
Representative(s)Grund, Martin
Grund Intellectual Property Group
Patentanwälte und Solicitor PartG mbB
Steinsdorfstraße 2
80538 München / DE
[N/P]
Former [2017/47]Grund, Martin
Grund Intellectual Property Group
Patentanwalt und Solicitor PartG mbB
Postfach 44 05 16
80754 München / DE
Former [2014/39]Grund, Martin
Grund
Intellectual Property Group
Postfach 44 05 16
D-80754 München / DE
Former [2012/20]Stephen, Robert John, et al
Olswang LLP 90 High Holborn
London WC1V 6XX / GB
Application number, filing date10797804.107.07.2010
[2017/47]
WO2010US41250
Priority number, dateUS20090223583P07.07.2009         Original published format: US 223583 P
[2012/20]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011005886
Date:13.01.2011
Language:EN
[2011/02]
Type: A1 Application with search report 
No.:EP2451459
Date:16.05.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 13.01.2011 takes the place of the publication of the European patent application.
[2012/20]
Type: B1 Patent specification 
No.:EP2451459
Date:22.11.2017
Language:EN
[2017/47]
Search report(s)International search report - published on:AU13.01.2011
(Supplementary) European search report - dispatched on:EP13.11.2013
ClassificationIPC:A61K31/337, A61K31/6615, A61K33/24, A61K31/282, A61K31/4745, A61K31/513, A61K31/7068, A61P35/00
[2017/15]
CPC:
A61K33/243 (EP,US); A61K31/6615 (US); A61K31/282 (US);
A61K31/337 (EP,US); A61K31/4745 (US); A61K31/513 (US);
A61K31/665 (EP,US); A61K31/7068 (US); A61K33/24 (EP,US);
A61K45/06 (EP,US); A61P1/16 (EP); A61P11/00 (EP);
A61P13/00 (EP); A61P13/12 (EP); A61P17/00 (EP);
A61P17/06 (EP); A61P17/12 (EP); A61P3/10 (EP);
A61P35/00 (EP); A61P43/00 (EP); A61P9/04 (EP) (-)
C-Set:
A61K31/337, A61K2300/00 (EP,US);
A61K31/665, A61K2300/00 (US,EP);
A61K33/24, A61K2300/00 (US,EP)
Former IPC [2013/49]A61K31/6615, A61K33/24, A61K31/337, A61P35/00, A61K45/06
Former IPC [2012/20]A61K31/6615, A61K33/24, A61K31/337, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/20]
Extension statesBANot yet paid
MENot yet paid
RSNot yet paid
TitleGerman:VERFAHREN ZUR REDUZIERUNG EINER MULTIRESISTENZ GEGEN ARZNEIMITTEL MITTELS INOSITOL-TRIPYROPHOSPHAT[2012/20]
English:METHOD OF REDUCING MULTI-DRUG RESISTANCE USING INOSITOL TRIPYROPHOSPHATE[2012/20]
French:MÉTHODE DE RÉDUCTION D'UNE RÉSISTANCE MULTIMÉDICAMENTEUSE À L'AIDE D'INOSITOL TRIPYROPHOSPHATE[2012/20]
Entry into regional phase07.02.2012National basic fee paid 
07.02.2012Search fee paid 
07.02.2012Designation fee(s) paid 
07.02.2012Examination fee paid 
Examination procedure07.02.2012Examination requested  [2012/20]
04.06.2014Amendment by applicant (claims and/or description)
23.07.2014Despatch of a communication from the examining division (Time limit: M06)
29.01.2015Reply to a communication from the examining division
22.07.2015Despatch of a communication from the examining division (Time limit: M06)
02.03.2016Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
11.05.2016Reply to a communication from the examining division
03.05.2017Communication of intention to grant the patent
30.08.2017Fee for grant paid
30.08.2017Fee for publishing/printing paid
30.08.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  23.07.2014
Opposition(s)23.08.2018No opposition filed within time limit [2018/44]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
11.05.2016Request for further processing filed
11.05.2016Full payment received (date of receipt of payment)
Request granted
06.06.2016Decision despatched
Fees paidRenewal fee
23.07.2012Renewal fee patent year 03
30.12.2013Renewal fee patent year 04
23.07.2014Renewal fee patent year 05
23.07.2015Renewal fee patent year 06
22.07.2016Renewal fee patent year 07
24.07.2017Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
31.07.201304   M06   Fee paid on   30.12.2013
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU07.07.2010
AL22.11.2017
AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
MK22.11.2017
NL22.11.2017
PL22.11.2017
PT22.11.2017
RO22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IS22.03.2018
GB07.07.2018
IE07.07.2018
LU07.07.2018
MT07.07.2018
BE31.07.2018
CH31.07.2018
FR31.07.2018
LI31.07.2018
[2020/33]
Former [2020/31]HU07.07.2010
AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
MK22.11.2017
NL22.11.2017
PL22.11.2017
PT22.11.2017
RO22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
GB07.07.2018
IE07.07.2018
LU07.07.2018
MT07.07.2018
BE31.07.2018
CH31.07.2018
FR31.07.2018
LI31.07.2018
Former [2020/27]HU07.07.2010
AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
PT22.11.2017
RO22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
GB07.07.2018
IE07.07.2018
LU07.07.2018
MT07.07.2018
BE31.07.2018
CH31.07.2018
FR31.07.2018
LI31.07.2018
Former [2020/16]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
GB07.07.2018
IE07.07.2018
LU07.07.2018
MT07.07.2018
BE31.07.2018
CH31.07.2018
FR31.07.2018
LI31.07.2018
Former [2020/08]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
GB07.07.2018
IE07.07.2018
LU07.07.2018
MT07.07.2018
BE31.07.2018
CH31.07.2018
FR31.07.2018
LI31.07.2018
Former [2019/23]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
GB07.07.2018
IE07.07.2018
LU07.07.2018
BE31.07.2018
CH31.07.2018
FR31.07.2018
LI31.07.2018
Former [2019/21]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
GB07.07.2018
IE07.07.2018
LU07.07.2018
CH31.07.2018
LI31.07.2018
Former [2019/19]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IE07.07.2018
LU07.07.2018
Former [2019/17]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
LU07.07.2018
Former [2019/15]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/52]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/40]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
SE22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/39]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
NL22.11.2017
PL22.11.2017
SE22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/37]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
NL22.11.2017
PL22.11.2017
SE22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/35]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
NL22.11.2017
SE22.11.2017
SK22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/24]AT22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
NL22.11.2017
SE22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/23]AT22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
NL22.11.2017
SE22.11.2017
NO22.02.2018
GR23.02.2018
Former [2018/22]ES22.11.2017
FI22.11.2017
LT22.11.2017
NL22.11.2017
NO22.02.2018
Documents cited:Search[Y]WO2007081315  (OXYPLUS INC [US], et al) [Y] 1-15 * page 12, lines 17-20 *;
 [A]  - FYLAKTAKIDOU K C ET AL, "Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, GB, (20050315), vol. 15, no. 6, doi:10.1016/J.BMCL.2005.01.064, ISSN 0960-894X, pages 1605 - 1608, XP004771154 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.bmcl.2005.01.064
 [Y]  - SAIARDI ADOLFO ET AL, "Inositol pyrophosphates regulate cell death and telomere length through phosphoinositide 3-kinase-related protein kinases", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (20050208), vol. 102, no. 6, ISSN 0027-8424, pages 1911 - 1914, XP002715367 [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.0409322102
 [Y]  - NG S S W ET AL, "INHIBITION OF PHOSPHATIDYLINOSITIDE 3-KINASE ENHANCES GEMCITABINE-INDUCED APOPTOSIS IN HUMAN PANCREATIC CANCER CELLS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20001001), vol. 60, no. 19, ISSN 0008-5472, pages 5451 - 5455, XP001084246 [Y] 1-15 * the whole document *
 [Y]  - HUANG CHUANSHU ET AL, "Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3' kinase", CANCER RESEARCH, (1997), vol. 57, no. 14, ISSN 0008-5472, pages 2873 - 2878, XP002715368 [Y] 1-15 * the whole document *
International search[X]WO2006102060  (OXYPLUS INC [US], et al);
 [X]  - BIOLO, A. ET AL., "Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (2009), vol. 106, no. 6, pages 1926 - 1929, XP008151127

DOI:   http://dx.doi.org/10.1073/pnas.0812381106
 [Y]  - KIEDA, C. ET AL., "Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (2006), vol. 103, no. 42, pages 15576 - 15581, XP008121655

DOI:   http://dx.doi.org/10.1073/pnas.0607109103
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.